Shearman & Sterling advised the underwriters of Axonics Modulation Technologies, Inc.’s initial public offering of 8 million shares of common stock at a public offering price of $15.00 per share, resulting in gross proceeds to the company of approximately $120 million.  The shares began trading on the Nasdaq Global Select Market under the ticker symbol “AXNX” on October 31, 2018.  

BofA Merrill Lynch and Morgan Stanley & Co. LLC acted as joint book-running managers for the offering, Wells Fargo Securities acted as lead manager and SunTrust Robinson Humphrey acted as co-manager.

Axonics Modulation Technologies, Inc. is a medical technology company focused on the design, development and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions for the treatment of overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Axonics has developed an innovative rechargeable SNM system for the treatment of patients with OAB, FI and UR.

The Shearman & Sterling team below was supported by associates Kathleen Mehary and Taylor Montgomery.

The Team